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Background
Allergic rhinitis with/without conjunctivitis (AR/C) suf-
ferers often rely on pharmacotherapy to relieve symp-
toms. Although the main goal of immunotherapy is
long-term disease modification, reducing or eliminating
the need for pharmacotherapy is also an important and
desirable treatment goal.
Methods
Data were pooled from two trials that evaluated the effi-
cacy and safety of short-ragweed sublingual immunother-
apy tablet (SLIT-T), MK-3641 (Ambrosia artemisiifolia;
Merck/ALK-Abelló). Subjects with ragweed-pollen–
induced AR/C were randomized ~16 weeks before the
2010 pollen season to once-daily MK-3641 (6 or 12 Amb
a 1-U doses; one trial also included a no-effect dose of 1.5
Amb a 1-U) or placebo. During the trial, all subjects,
whether taking MK-3641 or placebo, could use AR/C res-
cue medication, including oral/ocular antihistamines and
intranasal/oral corticosteroids. We examined rescue medi-
cation use in all groups.
Results
In pooled results from the two studies, 159 of 318 (50.0%)
subjects receiving MK-3641 12 Amb a 1-U and 144 of 324
(44.4%) subjects receiving 6 Amb a 1-U used no rescue
medication over the entire ragweed season, compared
with 109 of 340 (32.1%) subjects receiving placebo. These
differences represented 56% and 38% improvements over
placebo. Similarly, during the peak ragweed season 173 of
311 (55.6%) subjects and 161 of 317 (50.8%) subjects in
the 12 Amb a 1-U and 6 Amb 1-U groups, respectively,
reported no rescue medication use, in contrast to 136 of
333 (40.8%) subjects receiving placebo. Fewer subjects
taking 12 and 6 Amb a 1-U (28% and 19%, respectively)
used oral antihistamine than those taking placebo; 35%
and 28% fewer subjects used ocular antihistamine; and
43% and 27% fewer subjects used intranasal corticosteroid
(oral corticosteroid was used by <5 subjects in any group,
so rates were not calculated).
Conclusions
Compared with placebo, the SLIT-T treatment MK-3641
reduced rescue-medication use among subjects with rag-
weed-pollen–induced AR/C.
Trial registration
ClinicalTrials.gov Identifiers: NCT00783198; NCT00
770315.
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